Solvay Past Earnings Performance
Past criteria checks 0/6
Solvay has been growing earnings at an average annual rate of 26.4%, while the Chemicals industry saw earnings growing at 6.8% annually. Revenues have been declining at an average rate of 16.6% per year.
Key information
26.4%
Earnings growth rate
26.4%
EPS growth rate
| Chemicals Industry Growth | 6.0% |
| Revenue growth rate | -16.6% |
| Return on equity | -4.4% |
| Net Margin | -1.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Solvay makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,217 | -64 | 471 | 41 |
| 30 Jun 24 | 5,337 | 18 | 484 | 43 |
| 31 Mar 24 | 5,570 | 127 | 510 | 45 |
| 31 Dec 23 | 6,024 | -37 | 552 | 47 |
| 30 Sep 23 | 497 | -384 | -83 | -187 |
| 30 Jun 23 | 3,542 | -34 | 146 | -98 |
| 31 Mar 23 | 6,038 | 495 | 377 | -23 |
| 31 Dec 22 | 7,979 | 889 | 565 | 46 |
| 30 Sep 22 | 15,442 | 1,859 | 1,384 | 350 |
| 30 Jun 22 | 13,895 | 1,659 | 1,342 | 324 |
| 31 Mar 22 | 12,523 | 1,176 | 1,274 | 310 |
| 31 Dec 21 | 11,434 | 943 | 1,233 | 325 |
| 30 Sep 21 | 10,575 | 648 | 1,208 | 316 |
| 30 Jun 21 | 9,982 | 608 | 1,188 | 314 |
| 31 Mar 21 | 9,631 | -1,168 | 1,172 | 316 |
| 31 Dec 20 | 9,714 | -1,125 | 1,212 | 300 |
| 30 Sep 20 | 10,006 | -1,216 | 1,224 | 309 |
| 30 Jun 20 | 10,514 | -1,872 | 1,256 | 315 |
| 31 Mar 20 | 11,055 | -134 | 1,320 | 322 |
| 31 Dec 19 | 11,227 | -118 | 1,331 | 323 |
| 30 Sep 19 | 11,347 | 111 | 1,355 | 316 |
| 30 Jun 19 | 11,409 | 764 | 1,378 | 315 |
| 31 Mar 19 | 11,349 | 767 | 1,392 | 306 |
| 31 Dec 18 | 11,299 | 676 | 1,379 | 297 |
| 30 Sep 18 | 11,187 | 775 | 1,399 | 298 |
| 30 Jun 18 | 10,987 | 748 | 1,397 | 288 |
| 31 Mar 18 | 10,953 | 730 | 1,413 | 288 |
| 31 Dec 17 | 10,984 | 820 | 1,437 | 290 |
| 30 Sep 17 | 10,851 | 771 | 1,416 | 283 |
| 30 Jun 17 | 10,694 | 765 | 1,409 | 285 |
| 31 Mar 17 | 10,057 | 717 | 1,359 | 279 |
| 31 Dec 16 | 10,044 | 539 | 1,363 | 284 |
| 30 Sep 16 | 9,168 | 317 | 1,320 | 277 |
| 30 Jun 16 | 9,512 | 248 | 1,315 | 276 |
| 31 Mar 16 | 10,146 | 220 | 1,337 | 281 |
| 31 Dec 15 | 10,083 | 355 | 1,296 | 271 |
| 30 Sep 15 | 11,068 | 325 | 1,321 | 270 |
| 30 Jun 15 | 10,929 | 311 | 1,297 | 265 |
| 31 Mar 15 | 10,793 | 376 | 1,254 | 257 |
| 31 Dec 14 | 10,629 | 326 | 1,225 | 247 |
| 30 Sep 14 | 10,425 | 317 | 1,193 | 238 |
| 30 Jun 14 | 10,222 | 298 | 1,182 | 237 |
| 31 Mar 14 | 10,086 | 182 | 1,166 | 240 |
| 31 Dec 13 | 10,150 | 164 | 1,189 | 238 |
Quality Earnings: SOL is currently unprofitable.
Growing Profit Margin: SOL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOL is unprofitable, but has reduced losses over the past 5 years at a rate of 26.4% per year.
Accelerating Growth: Unable to compare SOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SOL is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-6.3%).
Return on Equity
High ROE: SOL has a negative Return on Equity (-4.37%), as it is currently unprofitable.